While they don't contact patients directly with personal social media accounts, physicians are aware of its importance with keeping patients updated.
"Our hospital uses Facebook and a couple of our docs have Twitter accounts they post on, but I don't have anything, certainly not for patients or the outside world.
The other difficulty with social media is that when I am at work, I'm at work; when I'm not at work, I'd rather not be, and it's just time consuming to try to keep up with those conversations."
"I live and practice in a rural area where it just wouldn't be used all that much.
I don't even have a personal Facebook page. I work in a community of 11,000 people who are all related to each other. I'd have to have 11,000 friends.
The hospital has a Web page, but they've just run the cables that give smartphones a signal in the past couple months. We don't even have a pager system that works out here in southern Illinois. Once that gets up and running, I may start using social media, because that is the way people communicate these days."
Mary Waller, MD
Olney, IL
"Of the 11 partners in our practice, three use Twitter. One uses it regularly, mostly about prostate cancer issues. He's younger and very media savvy.
I use it infrequently. I wrote a book about men's sexual health, and I tweet primarily to promote my book. My son actually does most of my tweeting for me.
I don't know how effective it is, but if you want to keep up with what's out there, it's another way of getting your message out.
I'm much more active in blogging. If you're promoting your practice, it's all about name recognition. It's important to get your name in front of the public, potential patients, and potential referring sources. So the more you tweet or blog, the more likely someone will remember you name when it's time to go to the urologist or to refer a patient."
Dudley Danoff, MD
Los Angeles
From evidence to practice: Dr. Makarov discusses implementation science in urology
July 25th 2024“What our major contribution is, I think as urologists doing implementation science, is determining the important questions, which we are particularly well-suited to do because we're taking care of the patients,” says Danil V. Makarov, MD, MHS.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.
From evidence to practice: Dr. Makarov discusses implementation science in urology
July 25th 2024“What our major contribution is, I think as urologists doing implementation science, is determining the important questions, which we are particularly well-suited to do because we're taking care of the patients,” says Danil V. Makarov, MD, MHS.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.
2 Commerce Drive
Cranbury, NJ 08512